Why the study?
Does maternal serum immunoreactive inhibin act as a marker for fetal Down's syndrome in second-trimester pregnancies?
Does maternal serum immunoreactive inhibin act as a marker for fetal Down's syndrome in second-trimester pregnancies?
Maternal serum immunoreactive inhibin is significantly elevated in second-trimester Down's syndrome pregnancies and may serve as a useful screening marker.
May support inhibin as a second-trimester Down syndrome marker; leaves open incremental value in prospective screening cohorts.
We measured immunoreactive inhibin in the maternal serum of 80 pregnancies with a chromosomally normal fetus and ten Down's syndrome pregnancies in the second trimester. The inhibin level in all Down's syndrome pregnancies was above the normal median; the multiple of the normal median (MoM) was 1.9. We found a statistically significant difference between the levels of inhibin in unaffected and affected pregnancies (Kolmogorov-Smirnov test: p < 0.002). Using an arbitrarily chosen cut-off of 2.4 MoM, 40 per cent of Down's syndrome and 5 per cent of the normal pregnancies were found. We conclude that immunoreactive inhibin may be useful as a marker for fetal Down's syndrome.
No takes yet. Share an insight, caveat, or question.
Lith et al. (1992) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: